A randomized phase III trial to determine the effect of consolidation with rituximab (IDEC C2B8 Mabthera) in patients with CD20+ follicular or mantle cell lymphoma having received induction therapy with rituximab weekly x 4

Font Standard Bold
Login

Research unit

SIAK

Project number

SAKK 35/98

Project title

A randomized phase III trial to determine the effect of consolidation with rituximab (IDEC C2B8 Mabthera) in patients with CD20+ follicular or mantle cell lymphoma having received induction therapy with rituximab weekly x 4

Texts for this project

	German	French	Italian
Key words	-	-	-
Short description	-	-	-
Transfer and application	-	-	-
Publications / Results	-	-	-
URL-addresses	-	-	-

Inserted texts

Category	Text
Key words (English)	SAKK Cancer oncology clinical trial Lymphoma CD20+ Rituximab Mabthera
Short description (English)	A randomized phase III trial to determine the effect of consolidation with rituximab (IDEC C2B8 Mabthera) in patients with CD20+ follicular or mantle cell lymphoma having received induction therapy with rituximab weekly x 4
Transfer and application (English)	Basis for evidence based oncological treatment
Publications / Results (English)	first publication: annales of Oncology 11 (Suppl.1) : 123-126, 2000 Related documents M. Ghielmini et al.: Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK), Annals of Oncology 16: 1675–1682, 2005. [PDF] 192 kB
URL-addresses (English)	http://www.siak.ch